Passive inhalation of dry powder influenza vaccine formulations completely protects chickens against H5N1 lethal viral challenge

There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

Graphical abstract

Abstract

Bird to human transmission of high pathogenicity avian influenza virus (HPAIV) poses a significant risk of triggering a flu pandemic in the human population. Therefore, vaccination of susceptible poultry during an HPAIV outbreak might be the best remedy to prevent such transmissions. To this end, suitable formulations and an effective mass vaccination method that can be translated to field settings needs to be developed. Our previous study in chickens has shown that inhalation of a non-adjuvanted dry powder influenza vaccine formulation during normal breathing results in partial protection against lethal influenza challenge. The aim of the present study was to improve the effectiveness of pulmonary vaccination by increasing the vaccine dose deposited in the lungs and by the use of suitable adjuvants. Two adjuvants, namely, Bacterium-like Particles (BLP) and Advax, were spray freeze dried with influenza vaccine into dry powder formulations. Delivery of dry formulations directly at the syrinx revealed that BLP and Advax had the potential to boost either systemic or mucosal immune responses or both. Upon passive inhalation of dry influenza vaccine formulations in an optimized set-up, BLP and Advax/BLP adjuvanted formulations induced significantly higher systemic immune responses than the non-adjuvanted formulation. Remarkably, all vaccinated animals not only survived a lethal influenza challenge, but also did not show any shedding of challenge virus except for two out of six animals in the Advax group. Overall, our results indicate that passive inhalation is feasible, effective and suitable for mass vaccination of chickens if it can be adapted to field settings.

Related collections

Most cited references 37

Record: found
Abstract: found
Article: not found

Probable limited person-to-person transmission of highly pathogenic avian influenza A (H5N1) virus in China.

Hua Wang, Zijian Feng, Yuelong Shu … (2008)

In December, 2007, a family cluster of two individuals infected with highly pathogenic avian influenza A (H5N1) virus was identified in Jiangsu Province, China. Field and laboratory investigations were implemented immediately by public-health authorities. Epidemiological, clinical, and virological data were collected and analysed. Respiratory specimens from the patients were tested by reverse transcriptase (RT) PCR and by viral culture for the presence of H5N1 virus. Contacts of cases were monitored for symptoms of illness for 10 days. Any contacts who became ill had respiratory specimens collected for H5N1 testing by RT PCR. Sera were obtained from contacts for H5N1 serological testing by microneutralisation and horse red-blood-cell haemagglutinin inhibition assays. The 24-year-old index case died, and the second case, his 52-year-old father, survived after receiving early antiviral treatment and post-vaccination plasma from a participant in an H5N1 vaccine trial. The index case's only plausible exposure to H5N1 virus was a poultry market visit 6 days before the onset of illness. The second case had substantial unprotected close exposure to his ill son. 91 contacts with close exposure to one or both cases without adequate protective equipment provided consent for serological investigation. Of these individuals, 78 (86%) received oseltamivir chemoprophylaxis and two had mild illness. Both ill contacts tested negative for H5N1 by RT PCR. All 91 close contacts tested negative for H5N1 antibodies. H5N1 viruses isolated from the two cases were genetically identical except for one non-synonymous nucleotide substitution. Limited, non-sustained person-to-person transmission of H5N1 virus probably occurred in this family cluster.

0 comments Cited 104 times – based on 0 reviews      Review now

Record: found
Abstract: found
Article: not found

Novel surface display system for proteins on non-genetically modified gram-positive bacteria.

Tjibbe Bosma, Rolf Kanninga, Jolanda Neef … (2006)

A novel display system is described that allows highly efficient immobilization of heterologous proteins on bacterial surfaces in applications for which the use of genetically modified bacteria is less desirable. This system is based on nonliving and non-genetically modified gram-positive bacterial cells, designated gram-positive enhancer matrix (GEM) particles, which are used as substrates to bind externally added heterologous proteins by means of a high-affinity binding domain. This binding domain, the protein anchor (PA), was derived from the Lactococcus lactis peptidoglycan hydrolase AcmA. GEM particles were typically prepared from the innocuous bacterium L. lactis, and various parameters for the optimal preparation of GEM particles and binding of PA fusion proteins were determined. The versatility and flexibility of the display and delivery technology were demonstrated by investigating enzyme immobilization and nasal vaccine applications.

0 comments Cited 75 times – based on 0 reviews      Review now

Record: found
Abstract: found
Article: not found

Advax™, a polysaccharide adjuvant derived from delta inulin, provides improved influenza vaccine protection through broad-based enhancement of adaptive immune responses.

Yoshikazu Honda-Okubo, Fadi Saade, Nikolai Petrovsky (2012)

Advax™ adjuvant is derived from inulin, a natural plant-derived polysaccharide that when crystallized in the delta polymorphic form, becomes immunologically active. This study was performed to assess the ability of Advax™ adjuvant to enhance influenza vaccine immunogenicity and protection. Mice were immunized with influenza vaccine alone or combined with Advax™ adjuvant. Immuno-phenotyping of the anti-influenza response was performed including antibody isotypes, B-cell ELISPOT, CD4 and CD8 T-cell proliferation, influenza-stimulated cytokine secretion, DTH skin tests and challenge with live influenza virus. Advax™ adjuvant increased neutralizing antibody and memory B-cell responses to influenza. It similarly enhanced CD4 and CD8 T-cell proliferation and increased influenza-stimulated IL-2, IFN-γ, IL-5, IL-6, and GM-CSF responses. This translated into enhanced protection against mortality and morbidity in mice. Advax™ adjuvant provided significant antigen dose-sparing compared to influenza antigen alone. Protection could be transferred from mice that had received Advax™-adjuvanted vaccine to naïve mice by immune serum. Enhanced humoral and T-cell responses induced by Advax™-formulated vaccine were sustained 12months post-immunization. Advax™ adjuvant had low reactogenicity and no adverse events were identified. This suggests Advax™ adjuvant could be a useful influenza vaccine adjuvant. Copyright © 2012 Elsevier Ltd. All rights reserved.

0 comments Cited 70 times – based on 0 reviews      Review now

All references

Author and article information

Contributors

Ben Peeters

Journal

Journal ID (nlm-ta): Eur J Pharm Biopharm

Journal ID (iso-abbrev): Eur J Pharm Biopharm

Title: European Journal of Pharmaceutics and Biopharmaceutics

Publisher: The Authors. Published by Elsevier B.V.

ISSN (Print): 0939-6411

ISSN (Electronic): 1873-3441

Publication date PMC-release: 9 October 2018

Publication date (Print): December 2018

Publication date (Electronic): 9 October 2018

Volume: 133

Pages: 85-95

Affiliations

[a ]Department of Pharmaceutical Technology and Biopharmacy, University of Groningen, Groningen, the Netherlands

[b ]Virology Division, Department of Infectious Diseases and Immunology, Utrecht University, Faculty of Veterinary Medicine, Utrecht, the Netherlands

[c ]Vaxine Pty Ltd., Flinders Medical Centre, Bedford Park, Adelaide 5042, Australia

[d ]Department of Diabetes and Endocrinology, Flinders University, Adelaide 5042, Australia

[e ]Department of Medical Microbiology, University of Groningen, University Medical Center Groningen, Groningen, the Netherlands

[f ]Wageningen Bioveterinary Research, Department of Virology, Houtribweg 39, 8221 RA, Lelystad, the Netherlands

Author notes

[* ]Corresponding author. ben.peeters@ 123456wur.nl

Article

Publisher ID: S0939-6411(18)30806-3

DOI: 10.1016/j.ejpb.2018.10.008

PMC ID: 7126314

PubMed ID: 30312742

SO-VID: 605b66b1-90b7-413e-8d2e-bf5120ff6e6c

License:

Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.

History

Date received : 26 June 2018

Date revision received : 1 October 2018

Date accepted : 8 October 2018

Passive inhalation of dry powder influenza vaccine formulations completely protects chickens against H5N1 lethal viral challenge

Read this article at